Two clinical studies, COMBI-d and COMBI-v, conducted on patients with metastasized melanoma and BRAF V600E and V600K mutations, showed a 5-year overall survival rate of 34% and a median overall survival time of 25.9 months with dabrafenib plus trametinib treatment [25]. The gene discussed is BRAF; the disease is melanoma.